Cardiovascular, Bleeding, and Mortality Risks in Elderly Medicare Patients Treated With Dabigatran or Warfarin for Nonvalvular Atrial Fibrillation
By D. Graham, M. Reichman, M. Wernecke, Rongmei Zhang, M. Southworth, Mark S Levenson, T. Sheu, Katrina Mott, M. Goulding, Monika Houstoun and 3 more. Circulation, 2015
656 citations recorded by the source corpus.
Subfields: Cardiology and Cardiovascular Medicine, Economics and Econometrics, Toxicology
View Paper: https://www.semanticscholar.org/paper/56669c60986c730bc5a4f05ba0b0583fcb23633f
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Cardiology and Cardiovascular Medicine
Citations in the corpus
- The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. (2018, positive): “Also for dabigatran, the net clinical benefit was maintained and total myocardial ischaemic events were not increased, which was further supported by the very large registry follow-up in 134 000 older patients treated with dabigatran or VKA, which did not reveal any increased risk for MI.(79,329) Si”
- 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. (2016, neutral): “Fortunately, we now have a growing evidence base regarding stroke risk in patients with one clinical risk factor (i.e. a CHA2DS2-VASc score of 1 for men, and 2 for women), although this relies largely on observed stroke rates in patients not receiving OAC.”